Literature DB >> 8500912

Kinetics of serum and ocular antibody responses in susceptible mice that received a secondary corneal infection with Pseudomonas aeruginosa.

M J Preston1, K Kernack, R S Berk.   

Abstract

When susceptible C57BL/6J mice were infected with Pseudomonas aeruginosa in one eye and then reinfected in the previously uninfected contralateral control eye either 4 or 8 weeks after the primary infection, approximately 20 to 30% of the mice receiving a 4-week reinfection regimen restored corneal clarity within 4 weeks, while almost all of the 8-week-reinfected mice restored corneal clarity within 3 to 6 days postinfection. However, the rate of bacterial clearance was the same in both sets of mice despite the presence of opsonophagocytic antibodies only in the 8-week-reinfected mice. As determined by enzyme-linked immunosorbent assay, immunoglobulin G was the major immunoglobulin in both serum and ocular tissue of both mouse sets, and the immunoglobulin G level was two- to fourfold higher after the 8-week secondary infection than in the 4-week-reinfected mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500912      PMCID: PMC280906          DOI: 10.1128/iai.61.6.2713-2716.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Immunoglobulins in the human eye. Location, type, and amount.

Authors:  M R Allansmith; C R Whitney; B H McClellan; L P Newman
Journal:  Arch Ophthalmol       Date:  1973-01

2.  Experimental bacterial keratitis in neutropenic guinea pigs: polymorphonuclear leukocytes in corneal host defense.

Authors:  M J Chusid; S D Davis
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

3.  Kinetics of serum, tear, and corneal antibody responses in resistant and susceptible mice intracorneally infected with Pseudomonas aeruginosa.

Authors:  M J Preston; K A Kernacki; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Further studies on the genetic control of murine corneal response to Pseudomonas aeruginosa.

Authors:  R S Berk; L D Hazlett
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

5.  Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.

Authors:  A S Kreger; D M Lyerly; L D Hazlett; R S Berk
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-06       Impact factor: 4.799

6.  Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  P Ames; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Genetic control of the murine corneal response to Pseudomonas aeruginosa.

Authors:  R S Berk; M A Leon; L D Hazlett
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

8.  Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.

Authors:  R S Berk; I N Montgomery; L D Hazlett
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  Experimental Pseudomonas aeruginosa Infection of the Mouse Cornea.

Authors:  J R Gerke; M V Magliocco
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

10.  [The significance of bacterial and host factors in corneal infections caused by Pseudomonas aeruginosa].

Authors:  K P Steuhl; G Döring; H J Thiel
Journal:  Fortschr Ophthalmol       Date:  1989
View more
  2 in total

1.  Inhibition of bacterial adherence to host tissue does not markedly affect disease in the murine model of Pseudomonas aeruginosa corneal infection.

Authors:  T S Zaidi; M J Preston; G B Pier
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

2.  Rapid and sensitive method for evaluating Pseudomonas aeruginosa virulence factors during corneal infections in mice.

Authors:  M J Preston; S M Fleiszig; T S Zaidi; J B Goldberg; V D Shortridge; M L Vasil; G B Pier
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.